Inovio (INO) has had an up-and-down month. Shares shot up nearly 70% by January 27, before slipping 25% in the subsequent two days. In one word: roller-coaster.The surge for the infectious disease fighter follows news that a grant of up to $9 million from the Coalition for Epidemic Preparedness Innovations (CEPI) has been awarded to the company for the development of a vaccine against 2019-nCoV, the strain of the virus spreading in China. The grant will go towards preclinical work for INO-4800, Inovio’s new vaccine matched to the outbreak strain, and followed by a phase 1 clinical trial for the […]